Related Experiment Video
Updated: Sep 30, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
[Should dyslipidemia be treated in the elderly and very old people?]
Sylvain Bétrisey1,2, Oliver Baretella1,2, Manuel Blum1,2
1Consultation des lipides, Clinique universitaire de médecine interne, Inselspital, Hôpital universitaire de Berne, 3010 Berne.
Insights
Statins effectively prevent cardiovascular disease recurrence. Their benefit in primary prevention for individuals over 70, especially those with comorbidities, remains unclear, requiring careful consideration of individual factors.
Area of Science:
- Cardiology
- Geriatrics
- Pharmacology
Background:
- Statins are proven for secondary cardiovascular prevention.
- Evidence for statins in primary prevention for adults over 70 is limited.
- Elderly patients with comorbidities are often excluded from clinical trials.
Purpose of the Study:
- To review the evidence on statin use in primary prevention for older adults.
- To discuss factors influencing the decision to initiate or discontinue statins in this population.
- To highlight the need for shared decision-making in clinical practice.
Main Methods:
- Literature review of existing studies and clinical trials.
- Analysis of factors relevant to clinical decision-making in elderly patients.
- Discussion of current recommendations and ongoing research.
Main Results:
- Statin benefits are well-established for secondary prevention.
- The efficacy and safety of statins for primary prevention in the elderly (over 70) are not clearly defined.
- Ongoing trials aim to clarify these benefits and risks.
Conclusions:
- Clinical decisions regarding statins in older adults require individualized assessment, including age, comorbidities, life expectancy, functional status, and patient preferences.
- Statin discontinuation is generally not recommended outside of clinical trials for this population.
Abstract:
The beneficial effect of statins on the risk of recurrence of cardiovascular disease (secondary prevention) is well demonstrated. In primary prevention (no symptomatic cardiovascular disease), the benefit of statins after the age of 70 years is less clear and elderly patients with comorbidities have often been excluded from large, randomized trials. Some ongoing clinical trials will provide more information on the potential benefits and risks of starting or stopping statins in older adults. In clinical practice, the decision to treat with statins needs to take into account age, comorbidities, life expectancy, functional and cognitive status and patient preferences (shared decision), but statin discontinuation is only recommended in the context of a clinical trial, as reviewed in this article.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Atherosclerosis III: Management
Lipids: Dietary Sources and Requirements
Coronary Artery Disease IV: Preventive Measures
Angina IV: Management
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...

